12 results on '"Rao, Chenfei"'
Search Results
2. Current treatment outcomes of congenital heart disease and future perspectives
- Author
-
Ma, Kai, He, Qiyu, Dou, Zheng, Hou, Xiaotong, Li, Xi, Zhao, Ju, Rao, Chenfei, Feng, Zicong, Sun, Kun, Chen, Xinxin, He, Yihua, Zhang, Hao, and Li, Shoujun
- Published
- 2023
- Full Text
- View/download PDF
3. Impact of coronary total occlusion on graft failure and outcomes of coronary artery bypass grafting
- Author
-
Lin, Shen, Rao, Chenfei, Yang, Limeng, Yang, Xupeng, Feng, Wei, Sun, Hansong, and Zheng, Zhe
- Published
- 2022
- Full Text
- View/download PDF
4. Is the era of the heart team coming?
- Author
-
Zheng, Zhe, Rao, Chenfei, and Du, Junzhe
- Published
- 2015
- Full Text
- View/download PDF
5. Effect of a smartphone-based intervention on secondary prevention medication prescriptions after coronary artery bypass graft surgery: The MISSION-1 randomized controlled trial.
- Author
-
Qu, Jianyu, Du, Junzhe, Rao, Chenfei, Chen, Sipeng, Gu, Dachuan, Li, Jing, Zhang, Heng, Zhao, Yan, Hu, Shengshou, Zheng, Zhe, and MISSION-1 Collaborative Group
- Abstract
Background: Studies found that patients who underwent coronary artery bypass grafting (CABG) often fail to receive optimal evidence-based secondary prevention medications. We evaluated the effectiveness of a smartphone-based quality improvement effort on improving the prescription of medical therapies.Methods: In this cluster-randomized controlled trial, 60 hospitals were randomized to a control arm (n = 30) or to an intervention arm using smartphone-based multifaceted quality improvement interventions (n = 30). The primary outcome was the prescription of statin. The secondary outcomes were prescription of beta-blocker, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker (ACE inhibitor or ARB), and optimal medical therapy for eligible patients.Results: Between June 1, 2015 and September 15, 2016, a total of 10,006 CABG patients were enrolled (5,653 in 26 intervention and 4,353 in 29 control hospitals, 5 hospitals withdrew). Statin prescribing rate was 87.8% in the intervention arm and 84.4% in the control arm. We saw no evidence of an effect of intervention on statin prescribing in the intention-to-treat analysis (odds ratio [OR], 1.31; 95% confidence interval (CI), 0.68-2.54; P = .43) or in key patient subsets. The prescription rates of ACE inhibitor or ARB and optimal medical therapy were comparable between study groups, while beta-blocker was more often prescribed in the intervention arm. Post hoc analysis demonstrated a greater increase in statin prescribing rate over time in the intervention arm.Conclusions: A smartphone-based quality improvement intervention compared with usual care did not increase statin prescribing for patients who received CABG. New studies focusing on the best practice of this technique may be warranted. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery.
- Author
-
Jianyu Qu, Heng Zhang, Chenfei Rao, Sipeng Chen, Yan Zhao, Hansong Sun, Yunhu Song, Sheng Liu, Liqing Wang, Wei Feng, Shuiyun Wang, Shengshou Hu, Zhe Zheng, Qu, Jianyu, Zhang, Heng, Rao, Chenfei, Chen, Sipeng, Zhao, Yan, Sun, Hansong, and Song, Yunhu
- Published
- 2021
- Full Text
- View/download PDF
7. Sinoatrial nodal artery injury in thoracoscopic epicardial ablation for atrial fibrillation.
- Author
-
Li, Haojie, Qu, Jianyu, Yu, Yitong, Zhang, Heng, Rao, Chenfei, Liu, Sheng, Zheng, Lihui, Lu, Bin, and Zheng, Zhe
- Subjects
ATRIAL fibrillation ,BODY surface mapping ,COMPUTED tomography ,SINOATRIAL node ,EXERCISE tests ,WOUNDS & injuries - Abstract
Open in new tab Download slide Open in new tab Download slide OBJECTIVES This study aimed to clarify the incidence of sinoatrial nodal artery (SANa) injury in thoracoscopic epicardial surgical ablation for atrial fibrillation (AF) and its impact on postoperative outcomes, which have not been previously elucidated. METHODS We enrolled 103 consecutively patients with AF who underwent thoracoscopic epicardial ablation at our institution. In these patients, we evaluated the postoperative incidence of SANa injury by using enhanced cardiac computed tomography. For patients with confirmed SANa injury, 3-day continuous electrocardiographic monitoring and exercise stress tests were performed to assess the sinus rhythm maintenance and sinus node function. RESULTS Thirteen patients (12.6%) had a confirmed SANa injury (left anterior type in 6 patients, left posterior type in 2 patients and double-branch type in 5 patients). After a median follow-up of 24 months, the patients with SANa injury were not found to be associated with lower sinus rhythm maintenance (hazard ratio 1.09, 95% confidential interval 0.36–3.31) as compared with those without SANa injury after adjustment for patient characteristics. Sinus node function was evaluated in 7 patients with SANa injury who remained in sinus rhythm after the procedure, and no sinus node dysfunction was confirmed in the 3-day electrocardiographic monitoring and exercise stress tests at a median follow-up of 12 months. CONCLUSIONS The prevalence of SANa injury in the patients who underwent thoracoscopic epicardial ablation for AF was relatively low, and the incidence of SANa injury was not associated with postoperative restoration of sinus rhythm and sinoatrial node dysfunction. More studies are required to better understand SANa injury. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Smartphone-based application to improve medication adherence in patients after surgical coronary revascularization.
- Author
-
Yu, Chunyu, Liu, Chongyang, Du, Junzhe, Liu, Hanning, Zhang, Heng, Zhao, Yan, Yang, Limeng, Li, Xi, Li, Jing, Wang, Jue, Wang, Huishan, Liu, Zhigang, Rao, Chenfei, Zheng, Zhe, and MISSION-2 Collaborative Group
- Abstract
Background: Secondary preventive therapies play a key role in the prevention of adverse events after coronary artery bypass grafting (CABG). However, adherence to secondary preventive drugs after CABG is often poor. With the increasing penetration of smartphones, health-related smartphone applications might provide an opportunity to improve medication adherence. We aimed to evaluate the effectiveness and feasibility of using a smartphone-based application to improve medication adherence in patients after CABG.Methods: The Measurement and Improvement Studies of Surgical coronary revascularizatION: medication adherence (MISSION-2) study is a multicenter randomized controlled trial that planned to enroll over 1000 patients who underwent isolated CABG at one of four large teaching hospitals in China; all enrolled participants had access to a smartphone and were able to operate at least three smartphone applications. The investigators randomly assigned the participants to one of two groups: (1) the intervention group with an advanced smartphone application for 6 months which was designed specifically for this trial and did not exist before. Participants could receive medication reminders and cardiac health education by the smartphone application or (2) the control group with usual care. The primary outcome was CABG secondary preventive medication adherence as measured by the translated Chinese version of the 8-item Morisky Medication Adherence Scale (MMAS-8) at 6 months after randomization. The secondary outcomes were mortality, major adverse cardiovascular and cerebrovascular events (MACCE), cardiovascular rehospitalization, self-reported secondary preventive medication use after 6 months of follow-up, blood pressure (BP), body mass index (BMI), and self-reported smoking status. All analyses were conducted using the intention-to-treat principle.Results: A total of 1000 patients (mean age, 57.28 [SD, 9.09] years; 85.5% male) with coronary heart disease after CABG were enrolled between September 2015 and September 2016 and were randomly assigned to the intervention (n = 501) or control group (n = 499). At 6 months, the proportion of low-adherence participants, categorized by MMAS-8 scores, was 11.8% in the intervention group and 11.7% in the control group (RR = 1.005, 95% CI 0.682 to 1.480, P = 1.000). Similar results were found in sensitivity analyses that considered participants who withdrew from the study, or were lost to follow-up as nonadherent. There were no significant differences in the secondary clinical outcome measures, and there were no significant differences in the primary outcome across the subgroups tested. In the intervention group, the proportion of participants who used and operated the application during the first month after CABG was 88.1%; however, the use rate decreased sharply from 42.5% in the second month to 9.2% by the end of the study (6 months).Conclusions: A smartphone-based application supporting secondary prevention among patients after CABG did not lead to a greater adherence to secondary preventive medications. The limited room for improvement in medication adherence and the low participants' engagement with the smartphone applications might account for these non-significant outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
9. Comparing Outcomes of Coronary Artery Bypass Grafting Among Large Teaching and Urban Hospitals in China and the United States.
- Author
-
Zhe Zheng, Heng Zhang, Xin Yuan, Chenfei Rao, Yan Zhao, Yun Wang, Normand, Sharon-Lise, Krumholz, Harlan M., Shengshou Hu, Zheng, Zhe, Zhang, Heng, Yuan, Xin, Rao, Chenfei, Zhao, Yan, Wang, Yun, and Hu, Shengshou
- Subjects
CORONARY heart disease surgery ,ACADEMIC medical centers ,CLINICAL medicine ,COMPARATIVE studies ,CORONARY artery bypass ,CORONARY disease ,HEALTH services accessibility ,HEALTH status indicators ,HOSPITAL utilization ,LENGTH of stay in hospitals ,HOSPITALS ,RESEARCH methodology ,EVALUATION of medical care ,MEDICAL cooperation ,PROBABILITY theory ,RESEARCH ,RESEARCH funding ,RISK assessment ,TIME ,URBAN hospitals ,EVALUATION research ,KEY performance indicators (Management) ,TREATMENT effectiveness ,ACQUISITION of data ,DISEASE prevalence ,HOSPITAL mortality ,ODDS ratio ,DIAGNOSIS - Abstract
Background: Coronary artery disease is prevalent in China, with concomitant increases in the volume of coronary artery bypass grafting (CABG). The present study aims to compare CABG-related outcomes between China and the United States among large teaching and urban hospitals.Methods and Results: Observational analysis of patients aged ≥18 years, discharged from acute-care, large teaching and urban hospitals in China and the United States after hospitalization for an isolated CABG surgery. Data were obtained from the Chinese Cardiac Surgery Registry in China and the National Inpatient Sample in the United States. Analysis was stratified by 2 periods: 2007, 2008, and 2010; and 2011 to 2013 periods. The primary outcome was in-hospital mortality, and the secondary outcome was length of stay. The sample included 51 408 patients: 32 040 from 77 hospitals in the China-CABG group and 19 368 from 303 hospitals in the US-CABG group. In the 2007 to 2008, 2010 period and for all-age and aged ≥65 years, the China-CABG group had higher mortality than the US-CABG group (1.91% versus 1.58%, P=0.059; and 3.12% versus 2.20%, P=0.004) and significantly higher age-, sex-, and comorbidity-adjusted odds of death (odds ratio, 1.58; 95% confidential interval, 1.22-2.04; and odds ratio, 1.73; 95% confidential interval, 1.24-2.40). There were no significant mortality differences in the 2011 to 2013 period. For preoperative, postoperative, and total hospital stay, respectively, the median (interquartile range) length of stay across the entire study period between China-CABG and US-CABG groups were 9 (8) versus 1 (3), 9 (6) versus 6 (3), and 20 (12) versus 7 (5) days (all P<0.001). This difference did not change significantly over time.Conclusions: In 2011 to 2013, there was no significant difference in in-hospital mortality among patients who underwent an isolated CABG surgery in large teaching and urban hospitals in China and the United States. The longer length of stay in China may represent an opportunity for improvement. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
10. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization:...
- Author
-
Rao, Chenfei, Du, Junzhe, Li, Xi, Li, Jing, Zhang, Heng, Zhao, Yan, Hu, Shengshou, Jiang, Lixin, Zheng, Zhe, and MISSION-1 Collaborative Group
- Abstract
Objectives: The benefits of secondary preventive drugs after coronary artery bypass grafting have been thoroughly established. However, the prescription rates of these drugs are low at discharge in China. We sought to evaluate the effectiveness of continuous quality improvement with mobile-based interventions for clinicians on improving the guideline-adherence of secondary preventive drugs prescription.Methods and Results: The quality MISSION-1 study is a cluster-randomized controlled trial. We enrolled 60 hospitals with a bypass surgery volume of more than 30 a year and randomly assigned them into the intervention group or the control group in a 1:1 ratio using minimized random grouping. The intervention group undertakes a series of mobile-based interventions, while the control group maintains a routine practice pattern. All sites consecutively register patients who underwent isolated coronary artery bypass grafting and submit in-hospital data. We require supporting documents regarding prescription information at discharge to adjudicate the outcome measures. The estimated sample size of enrolled patients is 9,600. The primary outcome measure is the prescription rate of statins for eligible patients at discharge. The secondary outcome measures are β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and optimal medical therapy. MISSION-1 study is now recruiting patients.Conclusions: The MISSION-1 study has the potential to identify the effectiveness of interventions on improving secondary prevention adherence at discharge after bypass surgery in China and further disseminate findings to other settings to improve the quality of care. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
11. The Chinese Cardiac Surgery Registry: Design and Data Audit.
- Author
-
Rao, Chenfei, Zhang, Heng, Gao, Huawei, Zhao, Yan, Yuan, Xin, Hua, Kun, Hu, Shengshou, and Zheng, Zhe
- Abstract
Background In light of the burgeoning volume and certain variation of in-hospital outcomes of cardiac operations in China, a large patient-level registry was needed. We generated the Chinese Cardiac Surgery Registry (CCSR) database in 2013 to benchmark, continuously monitor, and provide feedback of the quality of adult cardiac operations. We report on the design of this database and provide an overview of participating sites and quality of data. Methods We established a network of participating sites with an adult cardiac surgery volume of more than 100 operations per year for continuous web-based registry of in-hospital and follow-up data of coronary artery bypass grafting (CABG) and valve operations. After a routine data quality audit, we report the performance and quality of care back to the participating sites. Results In total, 87 centers participated and submitted 46,303 surgical procedures from January 2013 to December 2014. The timeliness rates of the short-list and in-hospital data submitted were 73.6% and 70.2%, respectively. The completeness and accuracy rates of the in-hospital data were 97.6% and 95.1%, respectively. We have provided 2 reports for each site and 1 national report regarding the performance of isolated CABG and valve operations. Conclusions The newly launched CCSR with a national representativeness network and good data quality has the potential to act as an important platform for monitoring and improving cardiac surgical care in mainland China, as well as facilitating research projects, establishing benchmarking standards, and identifying potential areas for quality improvements ( ClinicalTrials.gov No. NCT02400125 ). [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Preoperative clopidogrel and outcomes in patients with acute coronary syndrome undergoing coronary artery bypass surgery.
- Author
-
Qu, Jianyu, Zhang, Danwei, Zhang, Heng, Rao, Chenfei, Chen, Sipeng, Zhao, Yan, and Zheng, Zhe
- Abstract
The optimal preoperative antiplatelet strategy for patients with acute coronary syndrome (ACS) requiring surgical revascularization remains unclear because of competing risks of bleeding and ischemic events. We evaluated the effect of clopidogrel within 5 days before coronary artery bypass grafting (CABG) on outcomes in patients with ACS. Consecutive patients with ACS who underwent isolated CABG at a single center were included in this retrospective study. The primary outcome was a composite of death, myocardial infarction, and stroke within 30 days after surgery. Secondary outcomes were CABG-related major bleeding and perioperative transfusion. Inverse probability weighting using propensity score was performed to evaluate the risk-adjusted effect of preoperative clopidogrel on outcomes. Of 5543 patients with ACS, 820 (14.8%) patients continued clopidogrel within 5 days before CABG. After adjustment for differences in baseline factors, clopidogrel use ≤5 days before CABG was associated with significantly increased odds of the primary composite outcome (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.16-2.29; P =.005), stroke (OR, 3.13; 95% CI, 1.82-5.39; P <.001), major bleeding (OR, 2.01; 95% CI, 1.56-2.58; P <.001), and transfusion (OR, 2.05; 95% CI, 1.82-2.30; P <.001). The effects of preoperative clopidogrel use ≤5 days on primary outcome and major bleeding were greater in patients older than 65 years. Among patients with ACS undergoing CABG, clopidogrel therapy within 5 days before surgery was associated with increased odds of major cardiac and cerebrovascular events and bleeding complications than discontinuing clopidogrel for >5 days. A total of 5543 patients with ACS who underwent isolated CABG at a single center were included in the study. Compared with patients who had stopped clopidogrel for more than 5 days (N = 4723), those who continued clopidogrel within 5 days before CABG (N = 820) had significantly increased risks of 30-day major cardiac and cerebrovascular event (a composite of death, myocardial infarction, and stroke), major bleeding, and transfusion. The effects of preoperative clopidogrel use ≤5 days before CABG on the primary outcome and major bleeding were most profound in patients older than 65 years. The results of the present study highlight the necessity for a personalized preoperative antiplatelet strategy for patients with ACS requiring surgical revascularization. CABG , Coronary artery bypass grafting; ACS , acute coronary syndrome; IPW , inverse probability weighting; CI , confidence interval. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.